Opendata, web and dolomites


Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy

Total Cost €


EC-Contrib. €






Project "PEPTO1" data sheet

The following table provides information about the project.


Organization address
postcode: 8035
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PEPTOMYC SL ES (BARCELONA) coordinator 50˙000.00


 Project objective

Peptomyc S.L. is an SME created to develop a new, first-in-class, cancer therapy using innovative anti-Myc peptides. Myc is an oncogene deregulated in the majority of human cancers, making Peptomyc’s products potentially applicable to all cancer patients. The recombinant peptides are based on Omomyc, a Myc inhibitor benefiting from 20 years of preclinical validation as gene therapy. Omomyc displays remarkable therapeutic impact in multiple cancer models, with limited side effects, and no emergence of resistance. These peptides (Omomyc-CPP) developed by Peptomyc have unexpected cell-penetrating properties that make them excellent candidates for drug development. Three different drug products are being derived from the same drug substance, based on different administration routes, formulations and delivery devices. Peptomyc’s first mission is to take the first drug product (OMO-101) to completion of a successful phase I/II clinical trial, demonstrating safety and efficacy initially in glioblastoma (GBM) patients. Upon completion of phase I/II, Peptomyc plans to reach a licensing deal with a pharmaceutical company, to take care of further development and commercialization of OMO-101. In the feasibility study proposed here, Peptomyc’s team will elaborate and refine the business development plan of this new therapy to maximize its social and commercial potential. Such study will include: a. Management of the IPR strategy; b. Selection of the best CRO partners for [1] execution of safety studies, [2] clinical trials coordination, [3] Pre-IND and IND applications and other regulatory requirements; c. EMA Briefing meeting; d. Refinement of the business development plan, including market and risk analyses and costs. This feasibility study will be a strong asset to advance this unique, innovative therapy towards its commercialization not only in GBM, but eventually in multiple cancer markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PEPTO1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PEPTO1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More